Wedbush Has Bullish Forecast for Replimune Group Q3 Earnings

Replimune Group, Inc. (NASDAQ:REPL) – Analysts at Wedbush increased their Q3 2025 EPS estimates for shares of Replimune Group in a report released on Tuesday, November 12th. Wedbush analyst R. Driscoll now expects that the company will post earnings of ($0.68) per share for the quarter, up from their prior estimate of ($0.80). The consensus estimate for Replimune Group’s current full-year earnings is ($3.05) per share. Wedbush also issued estimates for Replimune Group’s Q4 2025 earnings at ($0.82) EPS, FY2025 earnings at ($3.10) EPS, Q1 2026 earnings at ($0.92) EPS, Q2 2026 earnings at ($0.89) EPS, Q3 2026 earnings at ($0.61) EPS, Q4 2026 earnings at ($0.61) EPS, FY2026 earnings at ($3.28) EPS, FY2027 earnings at ($2.26) EPS, FY2028 earnings at ($2.08) EPS and FY2029 earnings at ($1.38) EPS.

Several other equities research analysts also recently commented on REPL. Roth Mkm assumed coverage on Replimune Group in a report on Tuesday, August 27th. They set a “buy” rating and a $17.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $17.00 target price on shares of Replimune Group in a research note on Tuesday. Roth Capital raised Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Replimune Group presently has a consensus rating of “Buy” and a consensus target price of $16.80.

Replimune Group Trading Down 5.3 %

Shares of NASDAQ:REPL opened at $10.80 on Friday. Replimune Group has a 1-year low of $4.92 and a 1-year high of $12.97. The company has a 50 day moving average price of $11.46 and a 200 day moving average price of $9.54. The stock has a market capitalization of $738.94 million, a price-to-earnings ratio of -3.54 and a beta of 1.19. The company has a debt-to-equity ratio of 0.18, a quick ratio of 13.46 and a current ratio of 10.11.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.07.

Institutional Trading of Replimune Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC grew its position in Replimune Group by 10,304.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after purchasing an additional 4,946 shares during the last quarter. Point72 DIFC Ltd bought a new stake in shares of Replimune Group in the 2nd quarter worth about $57,000. Arizona State Retirement System bought a new stake in Replimune Group during the 2nd quarter worth approximately $108,000. Quest Partners LLC grew its holdings in shares of Replimune Group by 30.4% during the second quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after purchasing an additional 3,150 shares during the last quarter. Finally, Erste Asset Management GmbH bought a new stake in Replimune Group during the 3rd quarter worth about $133,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.